ClinicalTrials.gg
RecruitingNCT06841276QoLiDocUpdated Feb 4, 2026

Impact of QoLibri Medical Device on the Consequences of Chronic Pain: a Randomized Controlled Trial

An interventional study of QoLibri Digital Therapy in Chronic Pain, sponsored by Novesia. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Novesia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Chronic Pain with a site in France — 35 open to participants now, 39 under way, 2 of them phase 3. Chronic Pain · France.

Planned enrollment
7th of 67
410 · median 78
Started
2025
with 7 others
No phase
44 of 135
17 open now
Primary completion
2027-03
later than 13 of 38 live
Registered
117th of 135
by date

Among the 135 studies in Chronic Pain with a site in France, this one is the 7th largest by planned enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 44 with no phase, reaches primary completion later than 13 of the 38 other live ones, and was the 117th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

35 of the 135 studies in Chronic Pain with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Chronic Pain with a site in France, or all of them as a file.
02

Study summary

A superiority study evaluating the impact of the QoLibri Software as Medical Device on functional and psychological consequences of chronic pain in primary care patients. A prospective, cluster-randomized, wait list, controlled multicentre study with the main objective of evaluating the effectiveness of the QoLibri Digital Therapy on Quality of Life improvement in patients living with chronic pain.

03

Conditions studied

  • Chronic Pain

Keywords

  • pain, quality of life, functional impact, psychological impact, digital therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient experiencing at least moderate pain (on the Categorical Pain Scale) for more than 3 months
  • Patient with a BPI interference score ≥ 3 in at least 3 out of 7 dimensions
  • Patient with a smartphone and an internet connection at the place of use
  • Patient affiliated with a social security system or benefiting from such a system

Exclusion criteria

Exclusion Criteria:

  • Patient opposing participation in the study
  • Patient with severe anxiety and/or depressive disorders (especially a suicidal risk)
  • Patient presenting one or more barriers to the initiation of cognitive-behavioral therapy (significant social difficulties, low adherence to current care, insufficient memory or cognitive abilities, lack of time, lack of motivation...),
  • Adult patient under legal protection measures (guardianship, legal safeguard, psychiatric care, or deprived of liberty by judicial or administrative decision)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    QoLibri Digital Therapy

    Use of the QoLibri Digital Therapy on patient smartphone (on top of Treatment as Usual) for the 6-month experimental phase of the study

    Device: QoLibri Digital Therapy

  • No intervention
    Wait-list control

    Treatment as Usual for the initial 3-month experimental phase (wait list) and then Use of the QoLibri Digital Therapy on patient smartphone for the remaining 3-month experimental phase of the study

Interventions

  • DeviceQoLibri Digital Therapy

    A personalized program intended for chronic pain patients. It includes digitalized physical and psychological complementary approaches dedicated to symptoms management and quality of life improvement.

06

What researchers measure

Primary outcomes

  1. Effectiveness of QoLibri Digital Therapy

    Pain repercussions measured through the Pain Impact Score (PIS) which combines scores from 3 different domains evaluated by the PROMIS-29 (pain intensity, physical function, and pain interference) and quantifies the extent to which pain interferes with function and daily activities).

    Time frame: month 3

Secondary outcomes

  1. Reduction of pain repercussions

    Reduction of pain repercussions measured through the Pain Impact Score (PIS)

    Time frame: day 0, month 3, month 6

  2. Impact on Psychological Health

    Improvement in Mental Quality of Life measured by the MHS score

    Time frame: day 0, month 3, month 6

  3. Impact on Physical Health

    Improvement in Physical Quality of Life measured by the PHS score

    Time frame: day 0, month 3, month 6

  4. Overall Quality of Life

    Improvement in overall Quality of Life measured by the PROMIS-29 domain scores

    Time frame: day 0, month 3, month 6

  5. Global Impression of Change

    Evaluation of patient and clinician global impression of change measured by P-GIC and C-GIC

    Time frame: month 3, month 6

  6. Organizational impact

    Evaluation of care organization measured by an in-house questionnaire

    Time frame: day 0, month 3, month 6

  7. Evaluation of the perceived user experience

    Perceived user experience of the patient and the clinician measured by an in-house questionnaire

    Time frame: month 3, month 6

  8. Evaluation of the perceived severity of pain

    Perceived severity of the pain measured by the Categorical Pain Scale

    Time frame: day 0, month 3, month 6

07

Study locations

1 of 1 sites recruiting
  • Maison de santé Nailloux / Saint-Léon
    Nailloux, 31560, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Mar 2027, 25 months after the start.

Of 83 industry-sponsored interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 25 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 24, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06841276
Lead sponsor
Novesia
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Feb 28, 2025
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Alice Corteval, PharmD
Contact
a.corteval@novesia.fr
+33 6 88 08 29 72
Géraldine Batot, PhD
Contact
geraldine.batot@kyomed.com
Antoine Elyn, MD
principal investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion